Orgenesis, Inc. (OTCQB:ORGS) and Scott Carmer the Company’s U.S. CEO, is featured in the Special Report: Curing Diabetes. To view the segment please visit:https://www.youtube.com/watch?v=6JhXF0VIj50.
Over 350 million people worldwide are currently living with diabetes, a group all too familiar with the constant symptom management process that comes along with the diagnosis. One company, Orgenesis, isn’t content with just controlling the disease but has instead set out to cure it. The secret to ending diabetes may already be inside a patient’s own body. Corporate Profile Host, Annamaria Stewart, sat down with Scott Carmer to talk more about Orgenesis’ novel approach to curing diabetes.
Orgenesis’ regenerative approach to curing diabetes entails taking an adult cell and reprograming it to behave like a different cell. Namely, a select number of the diabetic patient’s own liver cells are turned into insulin producing pancreatic-like cells.
The treatment has the potential to make diabetics completely insulin independent, delivering a near normal a quality of life that unlike other diabetes treatments on the market aimed at disease management or slowing disease progression, Orgenesis’ technology may be the cure to diabetes.
About Corporate Profile
Corporate Profile(R) is a content provider for Huffington Post Outspeak Network, ConnectiMED TV Network, and ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.www.corporateprofile.com
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites